PD-L1 and checkpoint inhibitors have been front and center in the media relating to the treatment of cancer. Researches are now looking at the association with diabetes and metabolic disease.
| less than a minute read
Checkpoint Inhibitors and Diabetes
In patients with Type 1 diabetes, T cells in the immune system mistakenly attack islet cells in the pancreas that make insulin. Scientists at Boston Children’s Hospital have come up with a way to thwart this wayward autoimmune reaction, and it involves a protein that plays a prominent role in new immunotherapy treatments for cancer: PD-L1.